Nasdaq · Healthcare
Foghorn Therapeutics Inc. (FHTX)
As-reported financials and recent SEC filings for Foghorn Therapeutics Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$30.9M
Net income
$-74.3M
Net margin
—
Diluted EPS
$-1.18
ROE
68.5%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $-86.4M | $-102.7M | $-107.9M | $-117.1M | $-100.7M |
| Net income | $-74.3M | $-86.6M | $-98.4M | $-108.9M | $-101.3M |
| Diluted EPS | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →42026-06-25
View on EDGAR →Largest Healthcare peers
Go deeper on FHTX
Search Foghorn Therapeutics Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.